ライフサイエンスコーパス: underlying disease

1 hich may be due to early death driven by the underlying disease.

2 rofile for each PED subtype related to their underlying disease.

3 ting and medication use independent from the underlying disease.

4 to detect pairwise gene x gene interactions underlying disease.

5 Most associations were also dependent on the underlying disease.

6 llis is not a diagnosis, but it is a sign of underlying disease.

7 ow-up, including genetic testing, to exclude underlying disease.

8 ere low, and deaths resulted mostly from the underlying disease.

9 from inflammation and/or progression of the underlying disease.

10 se-free state, whereas 3% succumbed to their underlying disease.

11 itical role of biomarkers for diagnosing the underlying disease.

12 the continuation of medical treatment of the underlying disease.

13 merely reflect abnormalities induced by the underlying disease.

14 This characteristic was independent of the underlying disease.

15 trathecal IgG synthesis independently of the underlying disease.

16 an add substantially to the morbidity of the underlying disease.

17 tectable association of the pattern with the underlying disease.

18 ndings and outcomes according to the type of underlying disease.

19 ontrol group (n = 115, 2007-2008) with equal underlying disease.

20 llers or other drugs that do not address the underlying disease.

21 sting more than 14 days and unrelated to the underlying disease.

22 red to identify specific pathogenic variants underlying disease.

23 gulatory mechanisms and biological processes underlying disease.

24 pathophysiology and the regulatory networks underlying disease.

25 ic for this cell type and independent of the underlying disease.

26 llenges in the subsequent management of some underlying diseases.

27 iratory tract infections in individuals with underlying diseases.

28 s 36% and it correlated with the severity of underlying diseases.

29 inal CDIs is associated with the severity of underlying diseases.

30 l, 1.4-4.3]) when adjusted for age, sex, and underlying diseases.

31 on profiles may shed light on the mechanisms underlying diseases.

32 infusion, concomitant medications, age, and underlying diseases.

33 d stratified participants according to their underlying diseases.

34 atory tract infections, and exacerbations of underlying disease; 0.2%-11.5% of hospitalized patients

35 ples obtained from 296 patients with various underlying diseases (65% without underlying hematologica

36 Due to the broad spectrum of underlying diseases, a multidisciplinary approach is nec

37 Survival was also analyzed by underlying disease-acute liver failure (ALF) and chronic

38 tion remain elusive, and genomic alterations underlying disease advancement have only been identified

39 may reflect reverse causality, in which the underlying disease alters biomarker levels or shared phy

40 Depending on the underlying disease and mechanisms, eosinophil infiltrati

41 There was one maternal death attributed to underlying disease and no neonatal deaths.

42 is in some part due to the treatment of the underlying disease and not related to the iron supplemen

43 subjects can be obtained by identifying the underlying disease and oxygenation index on conventional

44 ed these pQTLs to study molecular mechanisms underlying disease and physiological phenotypes.

45 immune deficiencies, which mainly depend on underlying disease and specific therapies.

46 he main reasons for a breakthrough event are underlying disease and subtherapeutic drug levels.

47 sive growth retardation independent from the underlying disease and the degree of natural protein res

48 These findings suggest that underlying disease and timing of initiation should be ca

49 delivered gene therapies designed to modify underlying disease and/or improve clinical symptoms have

50 that could be mistaken for recurrence of the underlying disease and/or unrelated arteriosclerotic vas

51 ibrosis develops as a consequence of various underlying diseases and presents a major diagnostically

52 of COVID-19: male, administrative personnel, underlying disease, and high-risk exposure.

53 Age, underlying disease, and HSCT type were significantly ass

54 e condition was interpreted to be due to the underlying disease, and immunosuppressive therapy was sc

55 well as factors specific to the patient, the underlying disease, and its treatment.

56 t itself, to its mode of administration, the underlying disease, and patient characteristics.

57 e tailored on the basis of disease severity, underlying disease, and prior therapies.

58 e for young children, three for persons with underlying disease, and two for pregnant women.

59 es, illuminating the molecular heterogeneity underlying diseases, and identifying new targets for the

60 rmal aging, decreased mobility, medications, underlying diseases, and rectal sensory-motor dysfunctio

61 in vivo and to identify molecular mechanisms underlying disease as a result of its mutation.

62 rhythms as a result of the severity of their underlying diseases as well as the intensive care unit e

63 of ventricular arrhythmias because of their underlying disease, as well as the placement and positio

64 l outcomes and risk of NV are related to the underlying disease associated with AVLs.

65 Underlying diseases associated with uveitis-related CME

66 FAM111A function that could help reveal the underlying disease-associated mechanisms.

67 g systems-level analyses to reveal processes underlying disease associations.

68 e clustered into 7 different groups based on underlying disease (asthma, nasal polyps or chronic rhin

69 oing to reveal susceptibility loci for their underlying disease-atherosclerotic disease-identificatio

70 h distinct proteomic signatures that reflect underlying disease attributes; these core signatures may

71 Underlying disease, baseline liver impairment, and conco

72 With the goal of downstaging underlying disease before alloSCT, AZA alone led to outc

73 arbitrary and not necessarily reflective of underlying disease biology or outcomes.

74 ng is allowing for a better understanding of underlying disease biology, improved diagnostic accuracy

75 genes and will provide needed insights into underlying disease biology.

76 ariants can provide insights into mechanisms underlying disease biology.

77 Assuming that the underlying disease burden was stable, only 30 of the 162

78 With the assumption of a constant underlying disease burden, only 8 of the 122 additional

79 When compared to those with the same underlying disease but not exposed to glucocorticoids, t

80 cus on treating the symptoms rather than the underlying disease cause.

81 While the mechanisms underlying disease caused by asymptomatic infections are

82 pts in beta-cell function could identify the underlying disease-causing genes, but large-scale studie

83 vidence for haploinsufficiency as the common underlying disease-causing mechanism for DFNA10-related

84 However, the underlying disease-causing mechanism remains uncertain.

85 ociated with many complex disorders, but the underlying disease-causing mechanisms often remain uncle

86 Because of high age and multiple underlying diseases, CDI-related mortality is difficult

87 is is partly determined by the nature of the underlying disease, comorbidities and other immunosuppre

88 Regardless of the underlying disease, compared to baseline, a statisticall

89 cause altered EV composition may reflect the underlying disease condition, circulating EVs can be exp

90 ty, temporal patterns, network structure and underlying disease connections between EA, AA and HL pop

91 ontrol with corticosteroids or radiotherapy, underlying disease continued in 71% of patients and led

92 Analysis of vascular risk factors and underlying diseases detected by questionnaire and standa

93 r understanding of the molecular alterations underlying disease development and progression.

94 e adding to our understanding of the biology underlying disease development and progression.

95 val to discharge, regardless of age, gender, underlying diseases (diabetes mellitus, chronic obstruct

96 Underlying disease diagnosis (lymphoid > myeloid) and re

97 nd further understand the genetic mechanisms underlying disease dynamics.

98 ardiac pacing, or treatments targeted at the underlying disease (e.g., acute coronary occlusion).

99 ical variables are often confounded with the underlying disease effects, which further hampers accura

100 Despite this, the mechanisms underlying disease emergence are still not fully underst

101 While understanding the mechanisms underlying disease emergence is likely to have critical

102 hed light on the causal molecular mechanisms underlying disease etiology.

103 could allow us to identify specific pathways underlying disease; explain disease heterogeneity by gro

104 laboratory parameters including age, gender, underlying disease, family history of cirrhosis or hepat

105 ith older age (median 8.6 vs. 4.7 years), no underlying disease, family with respiratory symptoms, pr

106 ith older age (median, 8.6 vs 4.7 years), no underlying disease, family with respiratory symptoms, pr

107 to be the most likely cause of death with no underlying disease found.

108 its frequency after specific techniques and underlying disease (four questions), its clinical conseq

109 wise type I error rate and power, depends on underlying disease-gene-environment associations, estima

110 se paraclinical tests aid in identifying the underlying disease has relevance to the practising clini

111 Whereas the detailed mechanisms underlying disease have yet to be fully elucidated, rece

112 germline NF1 gene mutation may be one factor underlying disease heterogeneity.

113 the TMA, with the treatment directed at the underlying disease if possible.

114 40.9%), and organ dysfunction related to the underlying disease in 10 (22.8%).

115 Hematological malignancy was the underlying disease in 103 (53%) patients, and 154 (79%)

116 Underlying disease included mostly malignancies (n = 296

117 susceptible individuals, such as those with underlying diseases including HIV/AIDS and cystic fibros

118 and mechanisms of pruritus of major systemic underlying diseases, including end-stage renal disease,

119 model to demonstrate that the progression of underlying disease increases the incidence, severity, an

120 riptomic approach for identifying mechanisms underlying disease initiation and progression.

121 entify homogeneous subsets of patients whose underlying disease is driven by a specific mechanism tha

122 Given the heterogeneity of the underlying diseases leading to intestinal obstruction da

123 Many underlying diseases, like myelodysplastic syndrome (MDS)

124 Physician monitoring of the infection and underlying diseases may not be as frequent despite the n

125 ects in animal models of RP depending on the underlying disease mechanism and that both effects are d

126 impaired lysosomal trafficking of PSAP is an underlying disease mechanism for NCL and FTLD due to GRN

127 However, the underlying disease mechanism in EFEMP2 mutations has not

128 4 may represent physical determinants of the underlying disease mechanism in inherited focal segmenta

129 The underlying disease mechanism in TTS is still unknown.

130 in basal-like breast cancer (BLBC), but the underlying disease mechanism is largely opaque.

131 n made, a comprehensive understanding of the underlying disease mechanism is still lacking.

132 Better understanding of the underlying disease mechanism(s) is an urgent need for th

133 rchers face the challenge of deciphering the underlying disease mechanism.

134 cle cells and TDP-43 loss-of-function as one underlying disease mechanism.

135 distinct class of patients with a different underlying disease mechanism.

136 pharmacokinetic; 2) pharmacodynamic; and 3) underlying disease mechanism.

137 st, there is little consensus concerning the underlying disease mechanism.

138 t biliary excretion has been proposed as the underlying disease mechanism.

139 tional alteration of the AP-2 complex as the underlying disease mechanism.

140 dies typically exclude these patients, their underlying disease mechanisms and appropriate treatment

141 ainable source of disease cells for studying underlying disease mechanisms and for use as drug screen

142 onal profiling of ARDS blood PMNs to explore underlying disease mechanisms and identify therapeutic t

143 Functional analysis proposed plausible underlying disease mechanisms and pinpointed ETS2 as a p

144 However, our insight into the underlying disease mechanisms and the development of nov

145 s provided a solid foundation for unraveling underlying disease mechanisms and the development of the

146 research is to identify the driving pathways underlying disease mechanisms and the heterogeneity of c

147 , has hampered our ability to understand the underlying disease mechanisms and to develop new therapi

148 n diseases is essential to understanding the underlying disease mechanisms and to developing therapeu

149 ssion profile of that cell type to elucidate underlying disease mechanisms and to identify novel targ

150 Although underlying disease mechanisms are not well understood, m

151 The underlying disease mechanisms are unclear, which complic

152 The underlying disease mechanisms are unclear; therefore, tr

153 disease are important for the exploration of underlying disease mechanisms as well as for testing nov

154 This is attributed to the complexity of the underlying disease mechanisms as well as to the unique b

155 ven within the normal range, consistent with underlying disease mechanisms differing across CVDs.

156 t delineation of clinical phenotypes and the underlying disease mechanisms might help guide diagnosti

157 trophic lateral sclerosis (ALS) that reflect underlying disease mechanisms might help in diagnosis, s

158 genetic variation have been documented, the underlying disease mechanisms remain poorly elucidated.

159 Although the underlying disease mechanisms remain unknown, glial cell

160 r cerebral small vessel disease, elucidating underlying disease mechanisms that may form the basis fo

161 A critical reappraisal of the underlying disease mechanisms, in particular the dynamic

162 six novel clinicopathobiological clusters of underlying disease mechanisms, with elevated mast cell m

163 el clusters that are associated with diverse underlying disease mechanisms, with increased mast cell

164 h performance characteristics independent of underlying disease mechanisms.

165 n compounds to uncover important clues about underlying disease mechanisms.

166 ations have provided great insights into the underlying disease mechanisms.

167 condition in terms of symptoms, course, and underlying disease mechanisms.

168 AR) with the aim of better understanding the underlying disease mechanisms.

169 tic patients might provide new insights into underlying disease mechanisms.

170 tion has made it difficult to understand the underlying disease mechanisms.

171 e routine toxicity testing and evaluation of underlying disease mechanisms.

172 al effects on cognitive symptoms and on some underlying disease mechanisms.

173 ularly defined subgroups that better reflect underlying disease mechanisms.

174 l validation, may help with the discovery of underlying disease mechanisms.

175 e development of drugs that do not interdict underlying disease mechanisms.

176 s understanding the roles of microbes in the underlying disease mechanisms.

177 arning a weight that better approximates the underlying disease model in a data-adaptive manner.

178 Recent discoveries have identified underlying disease-modifying molecular aberrations contr

179 ces were identified with regard to age, sex, underlying disease, mortality, emergency operation, fasc

180 adverse events were related to pregnancy and underlying disease; most laboratory abnormalities were G

181 Here, we contrast the underlying disease networks and pathological mechanisms

182 intestinal in nature and consistent with the underlying disease; no unexpected adverse reactions were

183 thic MCAS, where neither an allergy or other underlying disease, nor KIT-mutated mast cells are detec

184 mpression therapy, although exacerbations of underlying disease occurred in the first 6 months of tre

185 e events in period 1 (excluding worsening of underlying disease) occurred in 1.3% of patients receivi

186 r these mechanisms diverge between different underlying diseases of chronic pruritus (CP).

187 JAK-STAT signaling is part of the mechanism underlying disease onset and progression in dyW-/- mice.

188 Although the genetic determinants underlying disease onset remain unclear, epigenetic modi

189 s, cancer, and cardiovascular disorders, the underlying disease or associated therapeutic interventio

190 For patients in whom no underlying disease or hypereosinophilic syndrome is foun

191 patients were not withdrawn due to return of underlying disease or rejection episodes.

192 y to atherosclerosis development or reflects underlying disease or risk factors remains unclear.

193 In rats, this effect is independent of underlying disease or tissue injury.

194 95% CI, 1.4-20.9; P = .016), a rapidly fatal underlying disease (OR 4.4; 95% CI, 1.5-12.6; P = .006),

195 ideration of the primary mechanistic drivers underlying disease outcomes under various water use adap

196 to patient characteristics: age (P = 0.78), underlying disease (P = 0.30) and type of type of LTx (P

197 We show that underlying disease parameters cannot be inferred with co

198 t the most profound loss, but the mechanisms underlying disease pathogenesis are not fully understood

199 e, we review the virology of EBV, mechanisms underlying disease pathogenesis in PIDs, and development

200 es and cellular characteristics of LAM cells underlying disease pathogenesis remain elusive.Objective

201 Mechanisms underlying disease pathogenesis remain unknown.

202 ty for investigating the cellular mechanisms underlying disease pathogenesis, evaluating potential th

203 athology and which reveals novel features of underlying disease pathogenesis.

204 ion of the cellular and molecular mechanisms underlying disease pathogenesis.

205 expand our knowledge of evolutionary forces underlying disease pathogenesis.

206 rkinje cell dendritic morphology potentially underlying disease pathogenesis.

207 ns may ultimately be connected to mechanisms underlying disease pathologies and, potentially, provide

208 ther these variants are risk factors for the underlying disease pathology, including neuritic plaques

209 inate hitherto unknown functional mechanisms underlying disease pathology.

210 d light on the neurodevelopmental mechanisms underlying disease pathology.

211 Our findings suggest possible differences in underlying disease pathophysiology and challenges to ide

212 Whether exenatide affects the underlying disease pathophysiology or simply induces lon

213 us pointing to common inflammatory processes underlying disease pathophysiology.

214 ent; however, the fatality was attributed to underlying disease per the reporter.

215 ), prompting us to investigate the mechanism underlying disease persistence.

216 cal laboratory to identify sequence variants underlying disease phenotypes in patients.

217 nd mechanisms of host-microbial interactions underlying disease phenotypes.

218 ights into the genes and regulatory pathways underlying disease phenotypes.

219 The association could be driven by underlying disease physiology or medications used to tre

220 e 2: A 32-year old healthy Thai male without underlying disease presented with nodular scleritis and

221 l require continued research into mechanisms underlying disease prevention, pathogenesis, progression

222 in which the drive for sleep exists but the underlying disease prevents its full expression.

223 ity, but approaches to prevent or modify the underlying disease process are needed.

224 invites speculation that they may mediate an underlying disease process in NDDs, which in turn may be

225 transmitters, affective states, and even the underlying disease process of cancer.

226 We identified biomarkers relevant to the underlying disease process progression and response to t

227 trate on novel and safe ways to modulate the underlying disease process rather than stopping excess t

228 uman microbiome during sepsis, as well as an underlying disease process to mimic the characteristics

229 A better understanding of the underlying disease process will guide development of new

230 with DME, suggesting that regardless of the underlying disease process, high levels of VEGF can caus

231 branous nephropathy and thus suggest another underlying disease process, such as combined membranous

232 opathy may not always accurately reflect the underlying disease process.

233 HCM and DCM, noncontrast T1 mapping detects underlying disease processes beyond those assessed by LG

234 LE) and further to get new insights into the underlying disease processes for better clinical managem

235 iance was strongest in SZ, suggesting common underlying disease processes jointly affecting the cereb

236 ion and act as surrogate markers to identify underlying disease processes.

237 horn sheep populations to gain insights into underlying disease processes.

238 ntial to illuminate the molecular mechanisms underlying disease progression and response to treatment

239 ns available due to the fact that mechanisms underlying disease progression are not well understood,

240 een these two pathologies and the mechanisms underlying disease progression have remained unclear.

241 y be readily adapted to study the mechanisms underlying disease progression on all mucosal epithelia,

242 pid mediators of inflammation and resolution underlying disease progression.

243 cially in progressive MS, thereby reflecting underlying disease progression.

244 offer new insights into the molecular events underlying disease progression.

245 t this resonance may be a critical principle underlying disease propagation, with specific autoantige

246 The Pramipexole On Underlying Disease (PROUD) study was designed to identif

247 ties to promote survival and expansion, thus underlying disease recurrence and resistance to conventi

248 l effects depending on timing of initiation, underlying disease, regimen type, and route of administr

249 effectively reverse this defect, potentially underlying disease relapse.

250 s to identify neural circuits and mechanisms underlying disease-relevant phenotypes.

251 However, isolating the minority of variants underlying disease remains an important, yet formidable

252 on, in association with the treatment of the underlying disease, represents a valid approach that can

253 Characterization of the genetic components underlying disease resistance is a major research area i

254 Management of the underlying disease resulted in long-term remission of th

255 Identifying functional variants underlying disease risk and adoption of personalized med

256 er understanding of the molecular mechanisms underlying disease risk will improve genetic diagnosis,

257 nal efforts aiming to dissect the mechanisms underlying disease risk, mapping cis-regulatory elements

258 k to sex-specific neurodevelopmental changes underlying disease risk.

259 giogenesis remain difficult to separate from underlying disease sequelae.

260 However, mechanisms underlying disease severity and virulence in arenavirus

261 Although underlying disease severity could also play a role, avoi

262 sis of this virus and investigate mechanisms underlying disease severity variation in the absence of

263 icult to establish because of confounding by underlying diseases, severity of infection, and differen

264 actors for P. aeruginosa infections, whereas underlying disease, source of infection, and severity of

265 However, because the underlying disease-specific pruritogens and itch-specifi

266 Underlying disease states such as cardiovascular disease

267 To understand the regulatory pathways underlying diseases, studies often investigate the diffe

268 l annotation (E) including genetic defect or underlying disease/substrate, and the functional status

269 fants and children, but the etiopathogenesis underlying disease subtypes remains incompletely underst

270 the retina may sustain injury as a result of underlying disease such as diabetes, and/or the interact

271 nsion (PH), whether idiopathic or related to underlying diseases such as HIV infection, results from

272 al posterior medial temporal lobe due to the underlying disease, suggesting that it is the capacity o

273 ndings provide a novel molecular explanation underlying disease susceptibility associated with COX-2

274 ls experiencing a shocking incident, but the underlying disease susceptibility gene networks remain p

275 t, for the majority of these, the mechanisms underlying disease susceptibility remain unknown.

276 nt data defining the common genetic variants underlying disease susceptibility, and explore how impro

277 (GWAS) in PD have identified common variants underlying disease susceptibility, while gene expression

278 ulations in the RCTs were older and had more underlying diseases than those in the observational stud

279 ular events for decades, suggesting that the underlying disease that caused stroke at a young age con

280 The most common underlying disease that results in recurrence on treatme

281 impact on the clinical presentation and the underlying disease that triggers cryoglobulin formation.

282 but it can also identify pathogenic variants underlying diseases that are not being sought (secondary

283 Independently of the underlying disease, the development of pulmonary hyperte

284 When addressing the cause of underlying disease, the management of cardiogenic shock

285 hese findings suggest that regardless of the underlying disease, the presence of CXCR4(+)/IgG(+) PCs

286 prioritize and biologically interpret genes underlying disease traits of interest.

287 munities has made identifying the mechanisms underlying disease transmission and progression extremel

288 ndiagnosed chronic kidney disease (CKD) from underlying disease, treatment, or both.

289 use, whereas univariate analysis identified underlying disease, type of operation, and high levels o

290 Overall, chronic underlying disease was found in 71% of patients, among w

291 rocognition from the effects inherent to the underlying disease, we analysed the results from randomi

292 The main underlying diseases were acute leukemia (35.7%), lymphom

293 Underlying diseases were present in 91 (59.9%) patients;

294 Major underlying diseases were solid organ transplantation (24

295 The underlying diseases were Stevens-Johnson syndrome (22 ey

296 can therefore help identify novel mechanisms underlying disease, which can lead to new therapies.

297 entifies biological pathways relevant to the underlying diseases while the other 9 methods fail to ca

298 In these patients, treatment of the underlying disease will also increase platelet counts.

299 loss contributes to the functional deficits underlying diseases with a demyelinating component.

300 omparison with patients affected by the same underlying disease without HLH (disease controls [DCs])